Adaptive upregulation of BCL2 was determined in NAFLD (41), while there was a significant low level of BCL2 and elevated apoptosis in nonalcoholic steatohepatitis (NASH) (42). Here, BCL2 is linked to metabolic dysfunction-associated steatotic liver disease.